From the UCLA Stein Eye Institute, Los Angeles, California (Berlin); Glaucoma Institute of Beverly Hills, Beverly Hills, California (Berlin, Shakibkhou, Tilakaratna); Ostwestfalen-Lippe (OWL) Eye Clinic, Detmold, Germany (Giers); Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee (Groth).
J Cataract Refract Surg. 2022 Jul 1;48(7):838-843. doi: 10.1097/j.jcrs.0000000000000856.
To describe the 8-year results of excimer laser trabeculostomy (ELT) alone and ELT in conjunction with phacoemulsification (phaco).
University hospital.
Retrospective review.
308 nm excimer laser energy delivered through an intraocular fiber-optic probe created channels through the inner wall of Schlemm canal. 2 groups were studied: ELT alone and ELT + phaco. Inclusion criteria were adult patients with open-angle glaucoma or ocular hypertension on 1 or more intraocular pressure (IOP)-lowering medications and, in the ELT + phaco group, presence of visually significant cataract. Primary outcome measures were change of IOP from baseline and number of IOP-lowering medications.
164 eyes in 2 groups, ELT alone (n = 90) and ELT + phaco (n = 74), were followed up for 8 years. Baseline IOP was 22.17 ± 7.0 mm Hg and 21.9 ± 6.44 mm Hg in the ELT alone and the ELT + phaco groups, respectively. IOP in the ELT alone group decreased to 16.84 ± 5.2 mm Hg at 1 year (n = 69) and remained at 15.9 ± 3.5 (n = 19) at 8 years. IOP in the ELT + phaco group was 14.04 ± 4.1 mm Hg at 1 year (n = 63) and 13.7 ± 2.8 mm Hg at 8 years (n = 13). The number of IOP-lowering medications at baseline in the ELT alone group was 1.85 ± 0.8 and decreased to 1.19 ± 1.10 at 1 year and 1.4 ± 1.4 at 8 years. In the ELT + phaco group, it was 1.58 ± 0.8 at baseline and decreased to 0.97 ± 0.95 at 1 year and 1.85 ± 0.7 at 8 years.
ELT demonstrated long-term IOP lowering and decrease in the number of IOP-lowering medications. Benefits of this laser-based implant-free microinvasive glaucoma surgery procedure included a high safety profile and long-term efficacy.
描述单独准分子激光小梁成形术(ELT)和 ELT 联合超声乳化术(phaco)的 8 年结果。
大学医院。
回顾性研究。
通过眼内光纤探头输送 308nm 准分子激光能量,在施莱姆管内壁形成通道。研究了两组患者:ELT 单独治疗组和 ELT+phaco 联合治疗组。纳入标准为患有开角型青光眼或高眼压症的成年患者,需使用 1 种或多种降眼压药物,ELT+phaco 组患者存在视力明显的白内障。主要观察指标为从基线开始的眼压变化和降眼压药物的数量。
两组共 164 只眼,ELT 单独治疗组(n=90)和 ELT+phaco 联合治疗组(n=74)随访 8 年。ELT 单独治疗组的基线眼压为 22.17±7.0mmHg,ELT+phaco 联合治疗组为 21.9±6.44mmHg。ELT 单独治疗组的眼压在 1 年时降至 16.84±5.2mmHg(n=69),8 年时保持在 15.9±3.5mmHg(n=19)。ELT+phaco 联合治疗组的眼压在 1 年时为 14.04±4.1mmHg(n=63),8 年时为 13.7±2.8mmHg(n=13)。ELT 单独治疗组基线时的降眼压药物数量为 1.85±0.8,降至 1 年时的 1.19±1.10 和 8 年时的 1.4±1.4。ELT+phaco 联合治疗组基线时为 1.58±0.8,降至 1 年时的 0.97±0.95 和 8 年时的 1.85±0.7。
ELT 显示出长期的眼压降低和降眼压药物数量的减少。这种基于激光的无植入物微创青光眼手术的好处包括高安全性和长期疗效。